C₂N is interested in collaborating with biotechnology and pharmaceutical companies to use its in vivo labeling technique to quickly determine if drug candidates are affecting human metabolism of proteins and biomolecules in the brain. This may aid in the decision making process for considering whether a drug candidate should be advanced into clinical trials or if the drug needs further optimization. The technology may also help with the optimization of dosing and scheduling. Numerous other clinical applications of C₂N's technology are currently of ongoing investigation.

C₂N uses a custom software solution to track samples and procedures and to capture and analyze data. C₂N is willing to work with the IT department of sponsors to ensure that data from studies performed by C₂N can be submitted as evidence for FDA or other comparable agency regulatory filings. Thus, a study performed in collaboration with C₂N may not only provide data for decision making in trial design but may also be used as supportive evidence in one or more regulatory filings.